In this episode, I talk to Ethan Perlstein, a YC biotech founder who wants to make better drugs and financial incentives for curing rare diseases. We discuss the post-academic collapse in science careers, the financial abandonment of most rare diseases, and how crypto and AI could revolutionize drug development.

In this episode, I speak with Professor Francoise Baylis, a renowned Canadian bioethicist whose work lies at the intersection of applied ethics, health policy, and practice. We talk about the ethics of research on human embryos -- at what date the line should be drawn -- and whether it practically and morally makes sense to allow for human germline editing.

In this episode, I speak with George Church—pioneer of human genome sequencing, co-inventor of CRISPR, and founder of over 50 biotech startups—on the future of synthetic biology: virus-proof cells, multiplex gene editing, and what it takes to reverse aging. We talk Ginkgo’s trajectory, 23andMe’s missed opportunity, and why the next bio revolution will be built on AI, not pipettes.0:00 Intro to George Church 0:54 New Innovations in the Lab 4:34 Is Synthetic Bio Scalable? 11:44 Ginko Bioworks Failure 16:33 AI Drug Discovery 17:54 Genome Sequencing 22:37 23andMe: What Went Wrong26:11 Carrier Screening28:31 Dor Yesherim & Carrier Matching 31:52 Cost of Gene Therapies 34:20 Germline Editing ABOUT MEHi, my name is Shriya; I'm a sophomore at Harvard and the host of the Bio/Acc Podcast. I started this podcast out of the Harvard Bioethics Communication Initiative to conduct deeply researched interviews with the world's most interesting people in biotech.Produced by ‪@RishabJainSOCIAL LINKS:🎤 Listen on Spotify: https://open.spotify.com/episode/4m42...🎤 Listen on Apple: https://podcasts.apple.com/us/podcast...See our Website: https://bioacceleration.com/Connect w/ Shriya on Linkedin: www.linkedin.com/in/shriya-bhat-0b845b203Let us know what you think in the comments below! Subscribe to our channel for more podcasts.